Gastroenterology News

The combination of a ketogenic diet and an experimental MNK inhibitor may be able to shrink pancreatic cancer tumors, according to preliminary study findings.

The presence of mucosal damage on upper gastrointestinal endoscopy was associated with a 76% greater risk for developing Parkinson’s disease, underscoring the need for “increased vigilance” among these patients, according to a cohort study.

Professional fulfillment can be achieved through a culture of wellness, efficiency of practice in the workplace and personal resilience, according to a speaker at the Ending Clinician Burnout Global Summit.

Country-specific public health policies that target metabolic dysfunction-associated steatotic liver disease risk factors, such as food insecurity and physical activity, may play a key role in mitigating the global burden of disease.

In this special crossover podcast episode, Tuesday Night IBS host Jeffrey Roberts, MSEd, BSc, and Kate Scarlata, MPH, RDN, are joined live by William Chey, MD, and Amanda Lynett, MS, RDN, at FOOD the Main Course Conference in Ann Arbor, MI.

The FDA has granted breakthrough therapy designation to Arrowhead Pharmaceuticals’ plozasiran, coupled with diet, to decrease triglycerides in patients with familial chylomicronemia syndrome, according to a company release.

Modified FOLFIRINOX induction chemotherapy prior to standard chemoradiation, surgery and adjuvant chemotherapy improved outcomes for patients with locally advanced rectal cancer, according to a long-term analysis of a randomized phase 3 trial.

Hepatitis B e-antigen seroconversion in childhood and low hepatitis B surface antigen titers after seroconversion independently predicted functional cure in chronic HBV-infected patients followed from childhood through adulthood.

A Salmonella enteriditis outbreak linked to eggs has left dozens hospitalized in nine states, prompting a Wisconsin farm to recall all eggs supplied by their farm to retailers, foodservice distributors and individual customers.

Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.